医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

REVOLVE™ Fat Grafting System by Acelity Now Available in Europe

2015年06月29日 PM10:00
このエントリーをはてなブックマークに追加


 

SAN ANTONIO

Acelity, a global wound care and regenerative medicine company, announced today that its patented REVOLVE™ System is now available in Europe. REVOLVE™ System offers fast, efficient and secure fat tissue processing in a range of reconstructive procedures. Fat grafting involves harvesting and transferring adipose tissue or body fat from one area of the body to another. The technique is gaining in popularity with surgeons because it uses the patient’s own tissue to enhance volume.

REVOLVE™ System is designed to yield rapid, reliable results in high-volume procedures through the use of a simple, closed system that controls critical variables in fat grafting. The single-use device can be placed in the sterile field to facilitate more efficient processing, filtering and transferring of a patient’s own (autologous) fat tissue. It enables high-volume fat processing (up to 700ml lipoaspirate) in less than 10 minutes, offering the potential to reduce operating room (OR) procedure time.

“With this European launch, Acelity continues to set global benchmarks in bringing cutting edge technologies to patients and setting the bar for standard of care in fat grafting,” said Lesley Fronio, Vice President and Franchise Leader of Breast Reconstruction and Fat Grafting at Acelity. “As a global leader in regenerative medicine, we continue adding to our portfolio of fat grafting products to provide clinicians with the tools they need to perform the most up-to-date procedures, efficiently and effectively.”

REVOLVE™ System has been used in multiple fat grafting surgeries. REVOLVE™ System uses surgical mesh specifically designed to filter blood debris and fluid to attain clean and high quality adipose tissue for transfer. The device also has a proprietary “collagen string catcher,” which helps prevent clogging within syringe tips during adipose re-implantation and effectively enhances procedural speed and proficiency.

“Fat grafting shows tremendous promise for the future of plastic surgery, as it uses patients’ own fat cells instead of foreign material implants,” said Mr. Ash Mosahebi, MBBS FRCS MBA PhD FRCS Consultant and Hon Senior Lecturer Royal Free Hospital, London, U.K. “REVOLVE™ System helps clinicians efficiently process high volumes of fat tissue to produce quality natural fat product, ultimately helping patients achieve more natural-looking results.”

Acelity is focused on changing the practice of medicine with transformative technology and providing innovative healing solutions that restore patient lives. For more information about the REVOLVE™ System features and benefits, visit LifeCell.com.

About Acelity

Acelity is a global wound care and regenerative medicine company created by uniting the strengths of three companies, Kinetic Concepts, Inc., LifeCell Corporation and Systagenix Wound Management, Limited. We are committed to advancing the science of healing and restoring people’s lives. Available in more than 75 countries, the innovative and complementary Acelity product portfolio delivers value through solutions that speed healing and lead the industry in quality, safety and customer experience. Headquartered in San Antonio, Texas, Acelity employs more than 5,500 people around the world. We believe in enabling better futures for everyone. Please visit acelity.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150629005191/en/

CONTACT

Acelity
Corporate Communications
Sarah Swift, +44 (0)797 0742
696
sswift@acelity.com
or
Investor
Relations
Caleb Moore, +1-210-255-6433
caleb.moore@acelity.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • フェリングが微生物叢ベースのライブバイオ治療薬RBX2660に関する米国FDA諮問委員会会議の開催を発表
  • 辉凌宣布美国FDA咨询委员会就公司基于微生物群的在研活体生物疗法RBX2660召开会议
  • Taiwan Excellence Pavilion Showcasing at The AACC Expo (American Association for Clinical Chemistry) for the First Time
  • Cellworks Singula™ TRI Provides Superior OS Predictions for NSCLC Patients Beyond NCCN-Guideline Genomic Factors
  • 2022 International Symposium on Human Identification (ISHI) Keynote DeNeen L. Brown Outlines Search for Victims of 1921 Tulsa Race Massacre